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Abstract
Inflammation and metabolism are intrinsically linked with inflammatory stimuli
inducing metabolic changes in cells and, in turn, metabolic capacity determining
cellular inflammatory responses. Although well characterized in peripheral immune
cells there is comparatively less known about these “immunometabolic” responses
in astrocytes. In this study, we tested the hypothesis that the astrocytic inflamma-
tory response driven by nuclear factor-kappa B (NF-κB) signaling is dependent on
glycolytic metabolism. Using mouse primary cortical astrocyte cultures, we
assessed changes in cellular metabolism after exposure to lipopolysaccharide (LPS),
with cytokine ELISAs and immunoblotting being used to measure inflammatory
responses. Results indicate temporally distinct metabolic adaptations to pro-
inflammatory stimulation in astrocytes: 3 hr LPS treatment increased glycolysis but
did not alter mitochondrial metabolism, while following 24 hr of LPS treatment we
observed increased oxidative phosphorylation, and decreased glycolytic capacity
and glucose uptake, partly due to reduced glucose transporter 1 expression. Inhibi-
tion of NF-κB signaling with the IKK-beta inhibitor TPCA-1 prevented the LPS
induced changes to glycolysis and oxidative phosphorylation. Furthermore, TPCA-1
treatment altered both glycolysis and oxidative phosphorylation independently
from inflammatory stimulation, indicating a role for NF-κB signaling in regulation of
basal metabolism in astrocytes. Inhibition of glycolysis with 2-deoxyglucose signifi-
cantly attenuated LPS-induced cytokine release and NF-κB phosphorylation, indi-
cating that intact glycolysis is required for the full inflammatory response to LPS.
Together our data indicate that astrocytes display immunometabolic responses to
acute LPS stimulation which may represent a potential therapeutic target for neu-
roinflammatory disorders.
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1 | BACKGROUND
In peripheral immune cells of the myeloid and lymphoid lineage,
inflammatory stimuli differentially modulate metabolic pathways
including glycolysis and oxidative phosphorylation, with the full
immune response being dependent on the activity of these processes
(O'Neill, Kishton, & Rathmell, 2016; Russell, Huang, &
VanderVen, 2019). This bidirectional relationship between immune
and metabolic function has become known as “immunometabolism.”
Immunometabolism is emerging as a therapeutic target for disease,
leading to the repurposing of pharmaceuticals targeting cellular
metabolism (e.g., Metformin) for conditions including cancers (Singer,
Cheng, Kreutz, Ho, & Siska, 2018), Alzheimer's disease (Campbell
et al., 2018; Koenig et al., 2017), and autoimmune diseases such as
multiple sclerosis and lupus (Norata et al., 2015). Anti-inflammatory
drugs are also being investigated to treat metabolic diseases including
Type-2 diabetes and obesity (Goldfine et al., 2008; Goldfine
et al., 2010; Lee, Wollam, & Olefsky, 2018). Despite the therapeutic
potential of this approach, there is less understanding of whether the
same immunometabolic changes are also seen in the central nervous
system (CNS), most notably in astrocytes.
Astrocytes are important for the maintenance of the CNS microen-
vironment and are key regulators of neuronal activity and behavior,
resulting in physiological changes in the whole organism (Liddelow
et al., 2017). Astrocytes become inflamed in vivo in response to a broad
range of inflammatory conditions, including metabolic stress or infection,
and undergo a series of morphological and functional adaptations ter-
med astrogliosis (Sofroniew & Vinters, 2010; Zamanian et al., 2012).
Preventing inflammation in astrocytes through inhibition of the nuclear
factor-kappa B (NF-κB) signaling pathway can alter the pathophysiologi-
cal response to disease. For example, inhibition of NF-κB activity in glial-
fibrillary acidic protein (GFAP) expressing astrocytes promotes functional
recovery of spinal cord injury in mice, resulting in reduced glial scarring
and increased locomotor activity (Brambilla et al., 2005). Additionally, in
the context of metabolic disease, inhibition of astrocyte NF-κB signaling
in the mouse, by deleting IκB kinase β from GFAP expressing cells,
improves glucose tolerance and reduces obesity by promoting energy
expenditure (Douglass, Dorfman, Fasnacht, Shaffer, & Thaler, 2017).
Some existing evidence already links inflammation with changes in
cellular metabolism in astrocytes. In aging mice, increased NF-κB activity
in astrocytes correlates with elevated aerobic metabolism (Jiang &
Cadenas, 2014). Furthermore, in vitro studies in mouse primary astro-
cytes demonstrate that treatment with inflammatory cytokines increases
their glucose uptake, reduces intracellular glycogen stores, and increases
flux through the tricarboxylic acid (TCA) cycle and pentose phosphate
pathway (Bélanger, Allaman, & Magistretti, 2011; Gavillet, Allaman, &
Magistretti, 2008). In a related study, Meares et al. showed that decreas-
ing substrate availability to astrocytes in vitro, by limiting glucose and
pyruvate, reduces interferon-gamma-induced inflammatory responses
(Meares, Qin, Liu, Holdbrooks, & Benveniste, 2013). The anti-
inflammatory effect of reduced glucose or pyruvate availability was
replicated by pharmacological activation of the cellular energy sensor
AMP-activated protein kinase (AMPK) (Meares et al., 2013). Exposure to
nitric oxide, which can be an inflammatory factor in high concentrations
(Sharma, Al-Omran, & Parvathy, 2007), also enhances the activity of sig-
naling pathways which regulate glycolysis in astrocytes: hypoxia inducible
factor 1α and AMPK (Almeida, Moncada, & Bolaños, 2004; Brix, Mesters,
Pellerin, & Jöhren, 2012). Together these data suggest that astrocytes
rely on glycolysis to achieve full inflammatory activation, but to our
knowledge, this important question has never been directly examined.
We tested the hypothesis that the astrocytic inflammatory
response driven by NF-κB signaling is dependent on glycolytic metab-
olism. The impact of inflammation on energy metabolism in astrocytes
was investigated, including an examination of whether NF-κB signal-
ing plays a role in the regulation of astrocyte metabolism during
inflammation. Further understanding of the role of astrocyte metabo-
lism in the inflammatory response may open the opportunity for new
therapies for CNS disease.
2 | METHODS
2.1 | Reagents
Unless otherwise stated, all reagents were purchased from Sigma-
Aldrich (part of Merck, UK) or ThermoFisher Scientific (UK).
2.2 | Animals and ethics
All animal studies were conducted in accordance with the UK Animals
in Scientific Procedures Act 1986 (ASPA) and study plans were
approved by the institutional Animal Welfare and Ethical Review Body
at the University of Exeter. Mouse pups (postnatal Days 1–5) from
breeding pairs of C57BL6/J mice (Charles River, UK) were used to
produce cultures of primary astrocytes from the cortex; offspring of
both sexes were used. Mice were group housed on a 12:12 light–dark
cycle at 22 ± 2C, with unlimited access to standard laboratory rodent
diet (EURodent diet [5LF2], LabDiet, UK) and water.
2.3 | Primary astrocyte isolation and general cell
culture
Mouse primary cortical astrocytes (CRTAS) were isolated using the
method described by Schildge et al. (Schildge, Bohrer, Beck, &
Schachtrup, 2013). Immunocytochemistry confirmed that mature cul-
tures contained >99% GFAP-immunoreactive glial cells (supplemen-
tary Figure S1). As previously described (Vlachaki Walker et al., 2017),
cultures were maintained in Dulbecco's Modified Eagle's Media
(DMEM) containing 25 mM glucose and supplemented with 10%
vol/vol fetal bovine serum ([FBS] Seralabs; UK), 200 U/ml penicillin–
streptomycin and 8 mM L-glutamine. Cultures were maintained in a
humidified incubator at 37C with 5% CO2. Prior to experimentation
cells were seeded on poly-L-lysine (PLL; 4 μg/ml) coated plasticware
at an appropriate density. Then, 24 hr prior to experimentation cells
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were maintained in DMEM (Gibco; UK) supplemented with 10%
vol/vol FBS, 200 U/ml penicillin–streptomycin, 8 mM L-glutamine and
7.5 mM glucose. On the day of experimentation, cells were cultured
in serum free DMEM (Gibco; UK) containing 2.5 mM glucose.
2.4 | Cell treatments
Lipopolysaccharide (LPS; Escherichia coli O26:B6) was conjugated to
0.17 mM fatty acid and endotoxin free bovine serum albumin (BSA
[Roche]) in 150 mM NaCl for 1 hr prior to treatment of cells. BSA was
adjusted to pH 7.4 at 37C with 1 N NaOH. BSA conjugated LPS or
BSA vehicle were diluted 1:10 into DMEM to give a final concentra-
tion of 1 μg/ml LPS and 0.017 mM BSA. Where used, TPCA-1 (1 μM;
Tocris [UK]; IKK-β inhibitor) was diluted in 0.1% vol/vol DMSO vehi-
cle 2 hr prior to additional treatments. 2-deoxyglucose (2-DG;
10 mM; 0.1% vol/vol H2O) was applied 1 hr prior to additional treat-
ments, when used.
2.5 | Immunocytochemistry and culture purity
For immunocytochemical staining, CRTAS were plated on sterile PLL
coated 13 mm diameter glass coverslips at a density of 1 × 105 cells/
coverslip. After treatment, cells were fixed with 4% wt/vol parafor-
maldehyde for 30 min at 37C and permeabilized for staining by treat-
ment with lysine block (PBS, 0.02% vol/vol Triton-X100, 2% wt/vol
lysine) for 15 min. Purity of the CRTAS cultures was confirmed using
mouse anti-GFAP (1:1,000; Millipore; UK; #MAB360) and goat anti-
IBA1 (1:1,000; Abcam; UK; #ab5076) immunoreactivity. Both primary
and secondary antibodies were diluted in lysine block. Fixed and
permeabilized cells were incubated with each primary antibody over-
night (~18 hr) at 4C, sequentially. After incubation with GFAP pri-
mary antibody, coverslips were incubated with fluorescent secondary
donkey anti-mouse Alexafluor488 (1:500; Invitrogen; UK; #A-21202)
for 1 hr at room temperature. After incubation with IBA1 antibody
overnight, fixed cells were incubated with fluorescent secondary don-
key anti-goat Alexafluor594 (1:500; Invitrogen; UK; #A-11058) for
1 hr at room temperature. Both between and after antibody incuba-
tions, fixed cells were washed three times for 5 min with 1X PBS to
remove unbound antibody. Nuclei were stained with DAPI
(0.01 mg/ml). Coverslips were mounted in Fluoroshield Mounting
Medium (Abcam) and allowed to dry prior to imaging using wide-field
microscopy (DM4000B-M; 10x/0.30; Leica; UK). FIJI Cell Counter
plugin (Fiji Is Just ImageJ; (Schindelin et al., 2012; Schneider,
Rasband, & Eliceiri, 2012)) was used to manually count nuclei associ-
ated with GFAP or IBA-1 staining.
2.6 | Cell viability assay
Cells were seeded at a density of 3.5 × 105 cells/well in six well
plates. After 24 hr of treatment (described above in Section 2.4) cells
were dissociated with 0.05% trypsin–EDTA and transferred to flow
cytometry tubes where trypsin was neutralized with fluorescence
activated cell sorting (FACS) buffer (2% vol/vol FBS in 1X PBS). Cells
were centrifuged at 100g for 5 min and the supernatant was aspi-
rated. Cells were resuspended in FACS buffer and stained with
propidium iodide (2 μg/ml), which is taken into cells with disrupted
membranes, for 10 min at 4C. Uptake of dye was determined using
flow cytometry, with increased uptake representing cell death
(BD Accuri C6; BD Systems; 488 nm; 633/22 nm). Gating used is
shown in supplementary Figure S2a. Region of interest P1 in Plot
2 was used to select events classified as dead cells.
2.7 | Immunoblotting
Cells were plated at a density of 4.5 × 105 cells per 60 mm diameter
dish. After treatment, cells were washed with 1X PBS to remove
excess BSA. Cells were lysed and protein isolated with modified RIPA
buffer (supplementary methods S1) and centrifugation at 1.3 × 104g.
Protein content was estimated using the Bradford method according
to the manufacturer's instructions (BioRad; UK). Proteins were sepa-
rated on a 12% vol/vol acrylamide gel using SDS-PAGE and trans-
ferred to nitrocellulose membranes. Precision plus protein Dual color
standards (BioRad) were run on all gels and used to estimate protein
size. Membranes were blocked for 1 hr in Odyssey Blocking Buffer
(Tris-buffered saline [TBS]) (Licor; UK). Antibodies against proteins of
interest were made up in 2.5% wt/vol milk powder or 2.5% wt/vol
BSA in 1X TBS with 0.1% Tween (TBS-T) as detailed in supplementary
methods S2 and incubated with the membranes overnight at 4C.
GAPDH expression was used as a loading control. Antibodies against
GAPDH were incubated with membranes for 1 hr at room tempera-
ture (see supplementary methods S2 for further details). Expression of
total NF-κB was estimated by stripping (1X Re-Blot Plus Strong Solu-
tion; Millipore), blocking and reprobing the same membranes used to
assess phosphorylated NF-κB expression. Between antibody binding
steps, blots were washed three times for 5 min with TBS-T. Bound
antibody was detected with species specific fluorescent antibodies,
incubated with membranes for 1 hr at room temperature (see supple-
mentary methods S2 for further details). Protein was visualized using
the Li-Cor Odyssey scanner. Fluorescence from detected protein was
estimated with Image Studio software (V5.2; Licor). For NF-κB immu-
noblots, expression of phosphorylated NF-κB (normalized to GAPDH)
was represented as a ratio of phosphorylated NF-κB (normalized to
GAPDH):total NF-κB (normalized to GAPDH). Data are shown as fold
change from the mean of control groups.
2.8 | Media cytokine concentrations
Cells were plated at a density of 4.5 × 105 cells per 60 mm diameter
dish. Media was collected from cells after treatment and cytokine con-
centrations determined using DuoSet ELISAs (BioTechne; UK) against
mouse TNF-α, IL-6, and IL-10 as per the manufacturer's instructions.
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Cytokine concentrations were normalized to protein content, col-
lected and estimated using the Bradford method (BioRad) as described
above.
2.9 | Metabolic analyses
The metabolic rate of cells was determined by measuring the extracel-
lular acidification rate (ECAR) as a measure of glycolysis, and oxygen
consumption rate (OCR) as a measure of mitochondrial function using
the Seahorse Metabolic Bioanalyzer XFe96 (Agilent; UK). The day
before treatment cells were plated in 96 well Agilent Seahorse Culture
plates (Agilent) at 4 × 104 cells per well in supplemented DMEM (10%
vol/vol FBS, 200 U/ml penicillin–streptomycin, 8 mM L-glutamine,
and 7.5 mM glucose). After treatment, and 1 hr prior to experimenta-
tion, media was replaced with Seahorse XF DMEM medium (pH 7.4;
Agilent) supplemented with either L-glutamine (2 mM; Glycolytic
Stress Test) or L-glutamine (2 mM), glucose (2.5 mM), and sodium
pyruvate (2.5 mM; Mito Stress Test). Cells were incubated for 1 hr at
37C in a humidified non-CO2 incubator. Glycolytic rate and oxidative
metabolism were determined using Glycolytic Stress Tests and Mito
Stress Tests, respectively, as per the manufacturer's instructions
(Agilent).
2.9.1 | Glycolytic Stress Test
Cells were treated sequentially with glucose (10 mM), oligomycin
(1 μM), and 2-DG (50 mM). All treatments were rehydrated in Sea-
horse XF DMEM medium (pH 7.4; Agilent) supplemented with 2 mM
L-glutamine. Glycolytic rate describes the highest ECAR measurement
after addition of glucose. Glycolytic capacity describes the maximum
ECAR measurement after addition of oligomycin. Glycolytic reserve
was calculated as the difference between glycolytic capacity and
glycolytic rate.
2.9.2 | Mito Stress Test
Cells were treated sequentially with oligomycin (0.5 μM), carbonyl
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP; 1 μM), and
rotenone with antimycin A (R/A; 0.5 μM). All treatments were
rehydrated in Seahorse XF DMEM medium (pH 7.4; Agilent) sup-
plemented with L-glutamine (2 mM), glucose (2.5 mM), and sodium
pyruvate (2.5 mM). Basal respiration was calculated as OCR immedi-
ately prior to addition of oligomycin minus the lowest measurement
after addition of R/A. ATP production was calculated as the difference
between basal respiration and the lowest OCR measurement after
addition of oligomycin. Proton leak was calculated as the difference
between the lowest OCR measurement (after addition of oligomycin)
and the lowest OCR measurement after addition of R/A. Maximal res-
piration was calculated as the maximum OCR measurement after
FCCP addition, minus the lowest OCR measurement after R/A addi-
tion. Spare capacity was calculated as the difference between basal
respiration and maximal respiration. Coupling efficiency was ATP pro-
duction as a percentage of basal respiration.
2.10 | Glucose uptake, ATP, and glycogen content
measurements
Glucose uptake was determined using Glucose Uptake-Glo kit
(Promega) following the manufacturer's instructions. Cells were plated at
4 × 104 cells/well in 96 well plates. A total of 10 μM 2-DG was used,
while omission of 2-DG used as a negative control. Luminescence was
measured after 30 min incubation in detection reagent. Data are shown
as fold change from the mean of contemporaneous control groups.
Intracellular ATP (iATP) concentrations were quantified using the
ATPLite Two Step kit (PerkinElmer) following the manufacturer's
instructions with modifications as previously described (Vlachaki
Walker et al., 2017). Data are shown as fold change from the mean of
contemporaneous control groups.
Glycogen content was measured using the Glycogen Assay Kit
(Fluorometric; Cell Biolabs; UK). Cells were plated at 1× 106 cells/dish
in 100 mm Petri dishes. After treatment, cells were washed twice with
PBS to remove exogenous glucose, collected in PBS and snap frozen.
Cells were lysed through sonication at 4C (LOW, 10 cycles, 10 on/10
off) and centrifuged at 1.3 × 104g for 20 min at 4C. Supernatants
were used for glycogen quantification. The assay was carried out fol-
lowing the manufacturer's instructions in black 96 well plates, and
fluorescence was measured after 45 min incubation in the reaction
mix. Values below detection are reported as zero.
All plate-based assays were quantified using a PheraStar plate
reader (BMG).
2.11 | Mitochondrial membrane potential
Mitochondrial membrane potential was determined using
tetramethylrhodamine ethyl ester (TMRE) dye uptake. Cells were
plated in six well plates at 3.5 × 105 cells/well. After treatment
(as appropriate), cells were dissociated using 0.05% trypsin–EDTA.
Cells were transferred to flow cytometry tubes, and trypsin was neu-
tralized with FACS buffer (2% vol/vol FBS in 1X PBS). Cells were cen-
trifuged at 100g for 5 min and the supernatant was aspirated.
Treatment for 15 min with FCCP (10 μM; 0.04% vol/vol DMSO vehi-
cle in FACS buffer) at 37C prior to TMRE dye uptake was used as a
positive indicator of mitochondrial depolarization. Cells were
resuspended and incubated with TMRE (100 nM) in 0.04% vol/vol
DMSO vehicle and FACS buffer for 30 min at 37C prior to centrifu-
gation, aspiration of supernatant and resuspension in FACS buffer.
Cellular fluorescence was measured using flow cytometry (BD Accuri
C6; UK; 488 nm; 585/40 nm). Increased dye uptake correlates with
increased mitochondrial polarization. An example of the gating used is
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shown in supplementary methods S3. Events from P1 (Plot 1) were
shown on Plot 3. Mean fluorescence of events counted in M2 (Plot 3)
was taken as fluorescence of treatment group. M2 was determined as
fluorescence intensity greater than the fluorescence intensity from
the TMRE untreated control group. Data are shown as fold change
from the mean of contemporaneous vehicle-treated control groups.
F IGURE 1 Mouse primary cortical astrocytes displayed an inflammatory response to lipopolysaccharide (LPS). (a) Representative anti-
phospho-nuclear factor-kappa B (NF-κB) p65 (Ser536) (top) and anti-total NF-κB p65 (bottom) immunoblot after 3 hr treatment with 0.1 μg/ml
LPS with anti-GAPDH loading control. (b) Densitometric analysis of (a): anti-phospho-NF-κB p65 (Ser536) fluorescence as a ratio of anti-total NF-
κB p65 normalized to anti-GAPDH fluorescence and represented as fold change in fluorescence from the mean of vehicle-treated controls (n = 8).
(c) Extracellular TNF-α concentration 3 hr after LPS treatment (n = 6). (d) Extracellular IL-6 concentration 3 hr after LPS treatment (n = 6).
(e) Extracellular IL-10 concentration 3 hr after LPS treatment (n = 4). (f) Representative anti-phospho-NF-κB p65 (Ser536) (top) and anti-total NF-
κB p65 (bottom) immunoblot after 24 hr treatment with 0.1 μg/ml LPS with anti-GAPDH loading control. (g) Densitometric analysis of (f): anti-
phospho-NF-κB p65 (Ser536) fluorescence as a ratio of anti-total NF-κB p65 normalized to anti-GAPDH fluorescence and represented as fold
change in fluorescence from the mean of vehicle-treated controls (n = 8). (h) Extracellular TNF-α concentration 24 hr after LPS treatment (n = 6).
(i) Extracellular IL-6 concentration 24 hr after LPS treatment (n = 6). (j) Extracellular IL-10 concentration 24 hr after LPS treatment (n = 5).
Unpaired t test, ** p < .01, *** p < .001, **** p < .0001. Data are expressed as mean ± SEM [Color figure can be viewed at wileyonlinelibrary.com]
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2.12 | Data presentation and statistics
Data were processed using Microsoft Excel 2013. GraphPad Prism 8 was
used to present data and for statistical analyses. For comparisons between
two groups, unpaired t tests were used. For multiple comparisons, one-
way analysis of variance with post hoc Tukey's tests were used. A mini-
mum of three independent replicates were used for each study. Data are
presented as mean ± SEM. Statistical significance was taken as p < .05.
3 | RESULTS
3.1 | LPS stimulated NF-κB signaling and cytokine
secretion in mouse primary astrocytes
Compared to vehicle-treated control cells, NF-κB (p65) phosphoryla-
tion in astrocytes was increased 3 and 24 hr after LPS treatment
(113.8%, p = .0031 and 93.9%, p = .0058, respectively; Figure 1a,b
F IGURE 2 Lipopolysac-
charide (LPS) increased glycolytic
rate in mouse primary astrocytes
within 30 min posttreatment.
(a) Oxidative phosphorylation
rate, represented as oxygen
consumption rate (OCR) over
time, of cortical primary mouse
astrocytes (CRTAS). Treatment
point indicated by vertical dotted
line. LPS treatment compared
with vehicle-treated control
(0.017 mM fatty acid free bovine
serum albumin; n = 18, two
independent plates). (b) Area
under the curve (AUC) of OCR
after treatment with LPS
(unpaired t test, p > .05; n = 18,
two independent plates).
(c) Glycolysis represented as
extracellular acidification rate
(ECAR) over time of CRTAS after
treatment with LPS (n = 18, two
independent plates). (d) AUC of
ECAR after treatment with LPS
(unpaired t test, **** p < .0001;
n = 18, two independent plates).
(e) Mitochondrial membrane
potential represented as fold
change from mean of controls,
measured by
tetramethylrhodamine ethyl ester
(TMRE) dye uptake after 15 min
treatment with LPS. A total of
10 μM FCCP was used as a
positive control (one-way
analysis of variance [ANOVA]
with post hoc Tukey, ****
p < .0001; n = 4). (e) Fold change
in intracellular ATP (iATP) in
CRTAS after 15 min treatment
with LPS (unpaired t test, p > .05;
n = 4). (g) Glucose uptake by
mouse primary astrocytes after
15 min treatment with LPS
represented as fold change in
2DG6P (unpaired t test, p > .05;
n = 5). Data are expressed as
mean ± SEM [Color figure can be
viewed at wileyonlinelibrary.com]
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and Figure 1f,g; supplementary Figures S7a,b and S8a,b). After 3 hr of
treatment with LPS, astrocyte TNF-α release was increased (Figure 1c;
p < .0001) but neither IL-6 (Figure 1e) nor IL-10 (Figure 1g) release
were changed, in comparison to vehicle-treated controls. After 24 hr
of LPS treatment, astrocyte release of TNF-α, IL-6, and IL-10 were all
increased compared to vehicle-treated controls (p < .0001, p = .0002,
and p = .0028, respectively; Figure 1d,f,h). Astrocyte viability was not
negatively affected by treatment with LPS after 24 hr, with >90% cell
viability, in both LPS and vehicle-treated control groups (supplemen-
tary Figure S2b).
3.2 | LPS induced an acute increase in glycolytic
rate in mouse primary astrocytes
Following measurement of baseline, the astrocytes were treated with
LPS or vehicle and OCR (Figure 2a,b) and ECAR (Figure 2c,d)
measured every 6 min for 1 hr using the Seahorse Bioanalyzer XFe96.
No acute change in OCR was observed (Figure 2a,b), indicating that
oxidative phosphorylation was not altered. However, there was a
rapid 20% increase in ECAR indicating increased glycolytic rate
(Figure 2c,d). As a complementary measure of mitochondrial activity,
mitochondrial membrane potential was assessed 15 min after treat-
ment with LPS using TMRE dye uptake (Figure 2e). There was no
change in mitochondrial membrane potential in LPS-treated astro-
cytes compared to vehicle-treated controls (p = .58), while the
positive control, the mitochondrial oxidative phosphorylation
uncoupler FCCP, significantly reduced TMRE uptake by 72%
(p < .0001; Figure 2e). This suggests that the integrity of the
mitochondrial membrane was not immediately altered by LPS
treatment, and rate of proton flow across the membrane was
unaltered. Astrocyte iATP concentrations were also unchanged
after 15 min of treatment with LPS in comparison to vehicle-
treated controls (p = .31; Figure 2f). There was a 25% increase in
F IGURE 3 Glycolytic rate
and capacity were increased in
mouse primary cortical astrocytes
after 3 hr treatment with
lipopolysaccharide (LPS).
(a) Extracellular acidification rate
(ECAR) during Glycolytic Stress
Test of mouse primary cortical
astrocytes 3 hr after treatment
with LPS compared with vehicle-
treated control (0.017 mM fatty
acid free bovine serum albumin;
n = 30, two independent plates).
Glu = 10 mM glucose;
Oligo = 1 μM oligomycin;
2-DG = 50 mM 2-deoxyglucose.
(b) Glycolytic rate: change in
ECAR after treatment with
glucose (unpaired t test, * p < .05;
n = 30, two independent plates).
(c) Glycolytic capacity: change in
ECAR after treatment with
oligomycin (unpaired t test, *
p < .05; n = 30, two independent
plates). (d) Glycolytic reserve:
difference between glycolytic
rate and glycolytic capacity
(unpaired t test, p > .05; n = 30,
two independent plates).
(e) Glucose uptake after 3 hr
treatment with LPS as fold
change in 2DG6P luminescence
(unpaired t test, p > .05; n = 6).
Data are expressed as mean
± SEM [Color figure can be
viewed at wileyonlinelibrary.com]
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glucose uptake rate in the cells after 15 min treatment with LPS
in comparison to vehicle-treated controls; however, this did not
reach statistical significance (p = .24; Figure 2g).
3.3 | Changes to glycolytic metabolism were
maintained 3 hr after treatment with LPS in mouse
primary astrocytes
To further interrogate the changes in cellular metabolism related to
inflammation, mouse primary astrocytes were treated with LPS for 3 hr
and subjected to a Glycolytic Stress Test. Glycolytic rate and capacity
were both significantly increased by 26% (p = .0138) and 20% (p = .025),
respectively (Figure 3a–c). This change in extracellular acidification was
unlikely to be due to dissolved CO2 from oxidative phosphorylation, as
OCR was not increased during the same treatment protocol (supplemen-
tary Figure S3). However, while the glucose uptake assay indicated a
10% increase (Figure 3e) in cells treated with LPS for 3 hr compared to
vehicle-treated controls, this was not statistically significant (p = .46).
The glycolytic reserve was unchanged between LPS-treated astrocytes
and vehicle-treated controls (Figure 3d).
The Mito Stress Test was used to evaluate mitochondrial function
after 3 hr of LPS treatment and no changes were observed compared
to vehicle-treated controls (supplementary Figure S3a,d–h). Further-
more, 3 hr of LPS treatment did not impact TMRE uptake compared
to vehicle-treated astrocytes (supplementary Figure S3b), in contrast
F IGURE 4 Glycolytic
capacity in mouse primary
astrocytes was reduced after
24 hr lipopolysaccharide (LPS)
treatment. (a) Extracellular
acidification rate (ECAR) during
Glycolytic Stress Test of mouse
primary cortical astrocytes 24 hr
after treatment with LPS
compared with vehicle-treated
control (0.017 mM fatty acid free
bovine serum albumin; n = 44,
three independent plates).
Glu = 10 mM glucose;
Oligo = 1 μM oligomycin;
2-DG = 50 mM 2-deoxyglucose.
(b) Glycolytic rate: change in
ECAR after treatment with
glucose (unpaired t test, p > .05;
n = 44, three independent plates).
(c) Glycolytic capacity: change in
ECAR after treatment with
oligomycin (unpaired t test, ***
p < .001; n = 44, three
independent plates).
(d) Glycolytic reserve: difference
between glycolytic rate and
glycolytic capacity (unpaired
t test, **** p < .0001; n = 44,
three independent plates).
(e) Intracellular glycogen content
after 24 hr treatment with LPS
(unpaired t test, * p < .05; n = 4).
(f) Glucose uptake after 24 hr
treatment with LPS as fold
change in 2DG6P luminescence
compared to the mean of vehicle-
treated controls (unpaired t test,
** p < .01; n = 6). Data are
expressed as mean ± SEM [Color
figure can be viewed at
wileyonlinelibrary.com]
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to the FCCP-treated (positive control) cells which showed a 70%
reduction in TMRE uptake (p < .0001). This suggests that astrocyte
mitochondrial membrane integrity was unaltered, and coupling was
not impacted 3 hr after LPS treatment. iATP concentrations were
also unchanged (supplementary Figure S3). Together these data
suggest that while there were adaptive changes in glycolysis, mito-
chondrial metabolism was unchanged by 3 hr of treatment
with LPS.
F IGURE 5 Twenty-four hours exposure to lipopolysaccharide (LPS) increased mitochondrial respiration in mouse primary astrocytes.
(a) Oxygen consumption rate (OCR) during Mito Stress Test of mouse primary cortical astrocytes 24 hr after treatment with LPS compared
with vehicle-treated control (0.017 mM fatty acid free bovine serum albumin; n = 28–30, 2 independent plates). Oligo = 0.5 μM oligomycin;
FCCP = 1 μM; R/A = 0.5 μM rotenone/antimycin. (b) Mitochondrial membrane potential after 24 hr treatment with LPS as fold change from
the means of vehicle-treated controls measured by tetramethylrhodamine ethyl ester (TMRE) dye uptake. A total of 10 μM FCCP was used as
a positive depolarization control (one-way analysis of variance (ANOVA) with post hoc Tukey, **** p < .0001; n = 6). (c) Intracellular ATP
(iATP) after 24 hr treatment with LPS as fold change from the mean of vehicle-treated controls (unpaired t test, p > .05; n = 4). (d) Basal
respiration: difference in OCR prior to oligomycin injection and after rotenone/antimycin injection (unpaired t test, **** p < .0001; n = 28–30,
two independent plates). (e) Maximal respiration: difference in OCR after injection of FCCP and after rotenone/antimycin injection (unpaired
t test, *** p < .001; n = 28–30, two independent plates). (f) Spare capacity: difference in OCR between basal respiration (d) and maximal
respiration (e; unpaired t test, **** p < .0001; n = 28–30, two independent plates). (g) Proton leak: difference in OCR after oligomycin
injection and after rotenone/antimycin injection (unpaired t test, ** p < .01; n = 28–30, two independent plates). (h) ATP production:
difference in OCR prior to oligomycin injection and after oligomycin injection (unpaired t test, **** p < .0001; n = 28–30, two independent
plates). (i) Coupling efficiency: percentage of basal respiration (d) used for ATP production (h; unpaired t test, p > .05; n = 28–30, two
independent plates). Data are presented as mean ± SEM [Color figure can be viewed at wileyonlinelibrary.com]
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3.4 | The glycolytic capacity of mouse primary
astrocytes was reduced after 24 hr treatment with LPS
Mouse primary astrocytes were treated with LPS for 24 hr prior to
evaluation using the Glycolytic Stress Test. In contrast to the acute
(3 hr) treatment, after 24 hr of LPS treatment, there was no significant
difference in glycolytic rate between LPS- and vehicle-treated cells
(Figure 4a,b; p = .29). However, glycolytic capacity was reduced by 47%
in the LPS-treated astrocytes in comparison to vehicle-treated controls
(Figure 4c; p = .0002), resulting in a 97% decrease in glycolytic reserve
(Figure 4d; p < .0001). This was reflected in a 82% depletion of intracel-
lular glycogen (Figure 4e; p = .023). This reduction in glycogen stores
and glycolytic capacity may have been due, at least in part, to the 37%
reduction in the rate of glucose uptake seen in the 24 hr LPS-treated
cells, compared to vehicle-treated controls (Figure 4f; p = .0091). These
data show that after 24 hr of exposure to LPS, astrocytes undergo pro-
nounced changes in their cellular metabolism, characterized by a reduc-
tion in both the glucose uptake and glycolytic capacity.
3.5 | Mitochondrial respiration in mouse primary
astrocytes was altered after 24 hr of LPS treatment
Given the adaptive changes to glycolysis observed after 24 hr of LPS
treatment, the impact on mitochondrial metabolism was also investi-
gated. Treatment with LPS for 24 hr increased basal mitochondrial respi-
ration in astrocytes by 53% in comparison to vehicle-treated controls
(Figure 5a,d; p < .0001). Conversely, maximal mitochondrial respiration
was reduced by 27% (Figure 5e; p = .0003), resulting in a 79% reduction
in spare capacity (Figure 5f; p < .0001). Proton leak was increased by
54% (Figure 5g; p = .0019). Mitochondrial ATP production was increased
by 52% (Figure 5h; p < .0001) and total iATP levels were unchanged after
24 hr treatment with LPS compared to vehicle-treated cells (Figure 5c;
p = .48). The mitochondrial coupling efficiency was unchanged (Figure 5i)
and there was no difference in TMRE dye uptake between cells treated
with LPS for 24 hr and vehicle-treated controls (Figure 5b). This corrobo-
rates the observed absence of change in coupling efficiency. Together
these data suggest after 24 hr of LPS treatment basal mitochondrial
activity of mouse primary astrocytes is increased, despite reduced mito-
chondrial capacity. Combined with the results of the Glycolytic Stress
Test, these data suggest that astrocytes alter their metabolism to main-
tain iATP through altered substrate preference.
3.6 | Glucose transporter 1 expression was
reduced by 24 hr of LPS treatment in mouse primary
astrocytes
To investigate potential causes of the reduced glycolytic capacity
observed after 24 hr LPS treatment, glucose transporter 1 (GLUT1)
glucose transporter expression was quantified using immunoblotting.
After 3 hr of LPS treatment GLUT1 expression was not altered com-
pared to vehicle-treated controls (Figure 6a; supplementary
Figure S9a; p = .96). In line with the observed alterations in glycolytic
rate and capacity (Figure 4a–d) and in concordance with the glucose
uptake data (Figure 4f), 24 hr of treatment with LPS significantly
reduced GLUT1 expression in astrocytes compared to vehicle-treated
controls (Figure 6b; supplementary Figure S8b; p = .0044).
3.7 | NF-κB inhibition reduced baseline glycolytic
metabolism and prevented LPS induced increases in
glycolytic rate
In other cell types, NF-κB signaling is implicated in the regulation
of cellular metabolism (Goetzman & Prochownik, 2018;
F IGURE 6 Glucose transporter
glucose transporter 1 (GLUT1) expression
in mouse primary astrocytes was reduced
after 24 hr treatment with
lipopolysaccharide (LPS). GLUT1
expression quantified by immunoblotting
with anti-GLUT1 (Millipore) after 3 hr
treatment (a; n = 8) or 24 hr treatment (b;
n = 8) with 0.1 μg/ml LPS. Left:
Representative blot. Right: Densitometric
analysis normalized to GAPDH (Protein
Tech) and as fold change compared to
mean of vehicle-treated controls.
Unpaired t test, ** p < .01 [Color figure
can be viewed at wileyonlinelibrary.com]
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Sommermann, O'Neill, Plas, & Cahir-McFarland, 2011). To investi-
gate this in astrocytes, the IKK-β inhibitor TPCA-1, was used.
TPCA-1 inhibited the inflammatory response to LPS after 3 and
24 hr of treatment: TNF-α and IL-6 release were significantly
reduced by TPCA-1 (supplementary Figure S4a–d; p < .0001), which
also prevented the LPS-induced increase in NF-κB p65 (Ser536)
phosphorylation relative to total NF-κB (p65) expression at 24 hr
(supplementary Figure S4e,f, supplementary Figures S7c and S8c;
p < .0001). TPCA-1 treatment had no impact on cell viability (sup-
plementary Figure S2d; p = .95).
Astrocytes receiving the combined TPCA-1 and LPS (3 hr) treat-
ment displayed a 27% reduction in glycolytic rate compared to those
treated with LPS alone (Figure 7a,b; p < .0001) suggesting that NF-κB
signaling plays an instrumental role in the glycolytic response to LPS.
Importantly, treatment with TPCA-1 alone reduced glycolytic rate by
28% compared to vehicle-treated cells (Figure 7a,b; p < .0001). This
suggests that NF-κB signaling plays an important role in regulating
basal metabolism in astrocytes which may impact the extent of the
LPS-induced response. Glycolytic capacity was also significantly
reduced in TPCA-1 cells in the presence (29%; p < .0001) or absence
of LPS (36%; p < .0001) compared to controls (Figure 7c,d). This
resulted in a reduction of glycolytic reserve in TPCA-1 groups (32%
with LPS and 45% without LPS treatment; both p < .0001).
Compared to vehicle-treated controls, TPCA-1 treatment did not
change mitochondrial maximal respiration, proton leak, spare capacity,
or iATP in the presence or absence of LPS (supplementary Figure S5c,
d,f,h, respectively). However, TPCA-1 treatment with LPS significantly
increased basal respiration by 18% (supplementary Figure S5a,b;
p = .01), increasing mitochondrial ATP production by 21% (supplemen-
tary Figure S5e; p = .002).
3.8 | Metabolic consequences of prolonged
exposure to LPS were abolished through inhibition of
NF-κB signaling
TPCA-1 treatment did not alter astrocyte glycolytic rate after 24 hr in the
presence or absence of LPS (Figure 8a,b). Treatment with TPCA-1
F IGURE 7 – Inhibition of nuclear factor-kappa B (NF-κB) signaling attenuated the glycolytic response to lipopolysaccharide (LPS) after 3 hr.
(a) Extracellular acidification rate (ECAR) during a Glycolytic Stress Test of mouse primary cortical astrocytes after 2 hr pretreatment with NF-κB
inhibitor, TPCA-1 (1 μM) ± 3 hr LPS treatment (0.1 μg/ml) compared with vehicle-treated control (Ctrl; 0.017 mM fatty acid free bovine serum
albumin/0.01% vol/vol DMSO; n = 32, two independent plates). Glu = 10 mM glucose; Oligo = 1 μM oligomycin; 2-DG = 50 mM 2-deoxyglucose.
(b) Glycolytic rate: change in ECAR after treatment with glucose (one-way analysis of variance [ANOVA] with post hoc Tukey, **** p > .0001, ns
p > .05; n = 32, two independent plates). (c) Glycolytic capacity: change in ECAR after treatment with oligomycin (one-way ANOVA with post hoc
Tukey, * p < .05, ** p < .01, **** p > .0001; n = 32, two independent plates). (d) Glycolytic reserve: difference between glycolytic rate and glycolytic
capacity (one-way ANOVA with post hoc Tukey, *** p < .001, **** p < .0001; n = 32, two independent plates). Data are expressed as mean ± SEM
[Color figure can be viewed at wileyonlinelibrary.com]
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prevented the 24 hr LPS-induced decrease in glycolytic capacity (37%;
p = .0003; Figure 8c) and reserve (72%; p < .0001; Figure 8d), but TPCA-1
alone did not alter glycolytic capacity or reserve when compared to
vehicle-treated astrocytes. Additionally, the LPS-induced reduction in
GLUT-1 expression after 24 hr (−47%; p < .0001) was attenuated by
TPCA-1 pretreatment (Figure 8e,f; supplementary Figure S9c; p = .081).
In astrocytes TPCA-1 treatment reduced the 24 hr LPS-induced
increases in basal respiration (65%; p < .0001), proton leak (84%;
p < .0001), and mitochondrial ATP production (61%; p < .0001)
(Figure 9a,b,d,e). Maximal respiration was reduced by TPCA-1 in the
presence of LPS treatment (35%; p < .0001), which was greater than
the reduction induced by LPS alone (18%; p = .013). Treatment with
F IGURE 8 Inhibition of nuclear factor-kappa B (NF-κB) rescued the lipopolysaccharide (LPS) induced reduction in glycolytic capacity 24 hr
after treatment. (a) Extracellular acidification rate (ECAR) during a Glycolytic Stress Test of mouse primary cortical astrocytes after 2 hr
pretreatment with NF-κB inhibitor, TPCA-1 (1 μM) ± 24 hr LPS treatment (0.1 μg/ml) compared with vehicle-treated control (Ctrl; 0.017 mM
fatty acid free bovine serum albumin/0.01% vol/vol DMSO; n = 22–28, two independent plates). Glu = 10 mM glucose; Oligo = 1 μM oligomycin;
2-DG = 50 mM 2-deoxyglucose. (b) Glycolytic rate: change in ECAR after treatment with 10 mM glucose (one-way analysis of variance [ANOVA]
with post hoc Tukey, p > .05; n = 22–28, two independent plates). (c) Glycolytic capacity: change in ECAR after treatment with oligomycin (one-
way ANOVA with post hoc Tukey, *** p < .001, **** p < .0001; n = 22–28, two independent plates). (d) Glycolytic reserve: difference between
glycolytic rate and glycolytic capacity (one-way ANOVA with post hoc Tukey, **** p < .0001; n = 22–28, two independent plates).
(e) Representative blot immunoblot of glucose transporter 1 (GLUT1) expression with GAPDH loading control after 2 hr pretreatment with NF-κB
inhibitor TPCA-1 (1 μM) and 24 hr treatment with 0.1 μg/ml LPS. (f) Densitometric analysis of (e) (one-way ANOVA with post hoc Tukey, ****
p < .0001, n = 6). Data are expressed as mean ± SEM [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 9 Inhibition of nuclear factor-kappa B (NF-κB) altered mitochondrial respiration independently from lipopolysaccharide (LPS) treatment
after 24 hr. (a) Oxygen consumption rate (OCR) during a Mito Stress Test of mouse primary cortical astrocytes after 2 hr pretreatment with NF-κB
inhibitor, TPCA-1 (1 μM) ± 24 hr LPS treatment (0.1 μg/ml) compared with vehicle-treated control (Ctrl; 0.017 mM fatty acid free bovine serum
albumin/0.01% vol/vol DMSO; n = 30, two independent plates). Oligo = 0.5 μMoligomycin; FCCP = 1 μM; R/A = 0.5 μM rotenone/antimycin. (b) Basal
respiration: difference in OCR prior to oligomycin injection and after rotenone/antimycin injection (one-way analysis of variance [ANOVA] with post hoc
Tukey, **** p < .0001, * p < .05; n = 30, two independent plates). (c) Maximal respiration: difference in OCR after injection of FCCP and after rotenone/
antimycin injection (one-way ANOVA with post hoc Tukey, **** p < .0001, * p < .05; n = 30, two independent plates). (d) Proton leak: difference in OCR
after oligomycin injection and after rotenone/antimycin injection (one-way ANOVA with post hoc Tukey, *** p < .001; n = 30, two independent plates).
(e) ATP production: difference in OCR prior to oligomycin injection and after oligomycin injection (one-way ANOVA with post hoc Tukey, *** p < .001, *
p < .05; n = 30, two independent plates). (f) Spare capacity: difference in OCR between basal respiration (b) and maximal respiration (c; one-way ANOVA
with post hoc Tukey, **** p < .0001, * p < .05; n = 30, two independent plates). (g) Coupling efficiency: percentage of basal respiration (b) used for ATP
production (d; one-way ANOVA with post hoc Tukey, p > .05; n = 30, two independent plates). (h) Intracellular ATP (iATP) represented as fold change in
luminescence from the mean of vehicle-treated controls (one-way ANOVA with post hoc Tukey, p > .05; n = 4). Data are presented as mean ± SEM
[Color figure can be viewed at wileyonlinelibrary.com]
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TPCA-1 alone reduced basal respiration and ATP production by 25%
(p = .013) and 24% (p = .011), respectively (Figure 9a,f). TPCA-1
reduced maximal respiration by 33% (p < .0001), independently of
LPS treatment, suggesting that NF-κB signaling may play a role in nor-
mal mitochondrial metabolism, which was attenuated by TPCA-1.
TPCA-1 treatment attenuated the LPS-induced reduction in spare
F IGURE 10 Inhibition of glycolysis reduced lipopolysaccharide (LPS) stimulated cytokine release. (a) Representative anti-phospho-nuclear
factor-kappa B (NF-κB) p65 (Ser536) (top) and anti-total NF-κB p65 (bottom) immunoblot after 2 hr pretreatment with 10 mM 2-deoxyglucose
(2-DG) ± 3 hr treatment with 0.1 μg/ml LPS with anti-GAPDH loading control. (b) Densitometric analysis of (a): anti-phospho-NF-κB p65 (Ser536)
fluorescence as a ratio of anti-total NF-κB p65 normalized to anti-GAPDH fluorescence and represented as fold change in fluorescence from the
mean of vehicle-treated controls (n = 6). (c) Extracellular TNF-α concentration after 2 hr pretreatment with 10 mM 2-DG ± 3 hr LPS treatment
(n = 6). (d) Extracellular IL-6 concentration after 2 hr pretreatment with 10 mM 2-DG ± 3 hr LPS treatment (n = 6). (e) Extracellular IL-10
concentration after 2 hr pretreatment with 10 mM 2-DG ± 3 hr LPS treatment (n = 6). (f) Representative anti-phospho-NF-κB p65 (Ser536) (top)
and anti-total NF-κB p65 (bottom) immunoblot after 2 hr pretreatment with 10 mM 2-DG and 24 hr treatment with 0.1 μg/ml LPS with anti-
GAPDH loading control. For this experiment, the antibody used was sourced from NEB #8242, and used to probe a separate immunoblot from
that probed with anti-phospho-NF-κB antibody. (g) Densitometric analysis of (f): anti-phospho-NF-κB p65 (Ser536) fluorescence as a ratio of
anti-total NF-κB p65 normalized to anti-GAPDH fluorescence and represented as fold change in fluorescence from the mean of vehicle-treated
controls (n = 6). (h) Extracellular TNF-α concentration after 2 hr pretreatment with 10 mM 2-DG ± 24 hr LPS treatment (n = 6). (i) Extracellular
IL-6 concentration after 2 hr pretreatment with 10 mM 2-DG ± 24 hr LPS treatment (n = 6). (j) Extracellular IL-10 concentration after 2 hr
pretreatment with 10 mM 2-DG ± 24 hr LPS treatment (n = 6). One-way analysis of variance (ANOVA) with post hoc Tukey, ns p > .05, * p < .05,
** p < .01, **** p < .0001. Ctrl—vehicle control. Data are expressed as mean ± SEM [Color figure can be viewed at wileyonlinelibrary.com]
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capacity by 23% (Figure 9f; p < .0001). No significant change was seen
in coupling efficiency after treatment with TPCA-1 (Figure 9g). iATP
levels were not altered (Figure 9h).
3.9 | Inhibition of the metabolic response to LPS
attenuated cytokine release from mouse primary
astrocytes
To investigate the necessity of glycolytic metabolism for the astrocyte
inflammatory response, cells were pretreated with the non-
metabolizable glucose analogue, 2-DG (10 mM) prior to stimulation
with LPS. Confirming the inhibitory effect of 2-DG on glycolysis,
mouse primary astrocytes treated with 2-DG showed a 36% reduction
in ECAR (p < .0001) but no impact was observed on OCR (supplemen-
tary Figure S6). Then, 24 hr treatment with 2-DG caused a 2%
decrease in cell viability which, while statistically significant
(p < .0001; supplementary Figure S2c), was unlikely to explain the
observed changes in metabolism (supplementary Figure S6) and cyto-
kine release (Figure 10c–h). 2-DG pretreatment attenuated the LPS-
induced increase in NF-κB (p65) phosphorylation relative to total NF-
κB expression in astrocytes 3 hr after LPS treatment (Figure 10a,b;
supplementary Figures S7d and S8d; p = .007) and abolished the
response after 24 hr (Figure 10f,g; supplementary Figures S7e and
S8e; p = .0015). 2-DG treatment significantly reduced LPS-induced
release of TNF-α (Figure 10c,h; 3 hr p = .03, 24 hr p = .0118) and IL-6
(Figure 10d,i, p < .0001) from astrocytes at both 3 and 24 hr and
completely abolished IL-10 release at both time points (Figure 10e,j;
p < .0001).
4 | DISCUSSION
In common with the extensive published studies from peripheral
immune cells (Bantug, Galluzzi, Kroemer, & Hess, 2018; O'Neill
et al., 2016; Russell et al., 2019), our data indicate that astrocytes also
display immunometabolic responses. Increases in glucose uptake and
glycolytic metabolism were evident in astrocytes within minutes of
LPS treatment and by 3 hr post-LPS, the Glycolytic Stress Test rev-
ealed an increased rate of glycolysis and glycolytic capacity. Due to
the speed of the response, these changes are likely driven by
increased activity of glucose transporters and the rate limiting glyco-
lytic enzymes. Inhibition of NF-κB signaling with TPCA-1 abolished
the LPS-induced glycolytic response in astrocytes at 3 hr suggesting a
key role for this pathway in the observed response. Translocation of
GLUT transporters into the plasma membrane is regulated by NF-κB
signaling in other cell types (Sommermann et al., 2011). Although no
change in total GLUT1 expression was seen at 3 hr after LPS treat-
ment our studies, the subcellular localization of GLUT1 was not
assessed; therefore, increased localization of GLUT1 at the plasma
membrane cannot be ruled out. NF-κB signaling mediates increases in
expression of c-Myc, a transcriptional regulator of glycolytic genes
(Goetzman & Prochownik, 2018; La Rosa, Pierce, &
Sonenshein, 1994), in fibroblasts and of hexokinase II in sarcoma cells
(Londhe et al., 2018). Our results suggest that this pathway may also
contribute to the changes seen in astrocytes.
Chronic LPS exposure (24 hr) resulted in metabolic adaptations in
astrocytes, probably to maintain ATP production in the face of pro-
longed insult: Glycolytic capacity and reserve were reduced, but were
accompanied by increased mitochondrial metabolism. As the experi-
mental medium used for the Mito Stress Test was supplemented with
pyruvate, the increases in mitochondrial metabolism were unlikely to
be directly caused by the change in glycolysis reported at this time
point. The increase in mitochondrial metabolism was likely driven by
increased TCA cycling to enable utilization of alternate fuel sources as
it has previously been shown that astrocytes increase TCA cycle rate
after 48 hr treatment with IL-1β or TNF-α (Gavillet et al., 2008). We
did not measure consumption of alternative carbon sources in this
study so we cannot reliably ascertain how the TCA cycle is being sup-
plied in the absence of glucose or glycogen derived carbon in our
model. Amino acid availability has been demonstrated to be important
for immune responses in macrophages (Viola, Munari, Sánchez-
Rodríguez, Scolaro, & Castegna, 2019). Indeed, data from other groups
suggests that astrocytes increase metabolism of glutamate during
hypoglycemia (Hertz & Hertz, 2003; Nissen, Pajęcka, Stridh, Skytt, &
Waagepetersen, 2015). In our model, the astrocytes were sup-
plemented with glutamine; this may enable them to use amino acids
to maintain oxidative metabolism during inflammation or absence of
glucose, and this could be an interesting avenue for further studies.
In our study, TPCA-1 reduced the LPS-induced increase in mito-
chondrial activity, suggesting a regulatory role for NF-κB in astrocyte
mitochondrial metabolism. In other cell types, NF-κB promotes mito-
chondrial respiration through increased expression and stabilization of
p53 (Aleyasin et al., 2004; Fujioka et al., 2004; Mauro et al., 2011),
which may also be the case in astrocytes. p53 activity reduces tran-
scription of GLUT1 (Johnson & Perkins, 2012; Mauro et al., 2011;
Schwartzenberg-Bar-Yoseph, Armoni, & Karnieli, 2004), which in our
study was significantly reduced by chronic LPS treatment in a NF-κB-
dependent manner. This reduced GLUT1 expression may explain the
attenuated glycolytic capacity and glucose uptake we observed in
astrocytes exposed to LPS for 24 hr. We also reported a depletion of
intracellular glycogen stores after 24 hr of LPS treatment. This data
are consistent with data from other groups in astrocytes treated with
pro-inflammatory cytokines for 48 hr (Bélanger et al., 2011; Gavillet
et al., 2008). It is possible that restricting glucose uptake, through
downregulating GLUT1 expression, results in depletion of glycogen
stores and may be a mechanism by which astrocytes attempt to
reduce glycolytic activity to limit the inflammatory response. This con-
clusion is further supported by the increased concentrations of the
anti-inflammatory cytokine IL-10 measured at 24 hr, demonstrating
that astrocytes are attempting to mitigate the pro-inflammatory envi-
ronment by this timepoint.
A reduction in autocrine/paracrine actions of LPS-induced astro-
cyte cytokine production on metabolism is likely partially responsible
for the metabolic differences seen downstream of TPCA-1 inhibition.
However, our data indicating reduced mitochondrial metabolism in
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astrocytes treated with TPCA-1 for 24 hr also suggests an important
regulatory role for NF-κB signaling in basal astrocyte metabolism,
probably driven through the mechanism(s) discussed above. This is
supported by the observation that treatment with TPCA-1 alone
reduced glycolytic rate after 3 hr, suggesting NF-κB plays a role in
maintaining basal glycolytic flux in astrocytes. This decrease in glyco-
lytic rate was only evident after addition of glucose, suggesting that
after inhibition of NF-κB signaling astrocytes likely have reduced abil-
ity to take up exogenous glucose rather than impaired utilization of
internal glycogen stores. In addition to inhibiting NF-κB signaling,
TPCA-1 has also been reported to inhibit STAT3 signaling (Nan
et al., 2014), which can also regulate metabolic function during inflam-
mation (Poli & Camporeale, 2015). As such, a role for STAT3 signaling
in mediating the effects seen cannot be ruled out.
Blocking glycolytic function in astrocytes with 2-DG reduced
cytokine release and NF-κB (p65) phosphorylation after 24 hr LPS
treatment, suggesting reduced activity of the canonical NF-κB path-
way. However, NF-κB phosphorylation was still evident 3 hr after LPS
treatment despite glycolytic inhibition, perhaps suggesting a role for
autocrine/paracrine actions of residual cytokine production in perpet-
uating the inflammatory response. The initial production of cytokines
may be reduced due to 2-DG associated suppression of other inflam-
matory pathways. For example, the glycolytic enzyme pyruvate kinase
isoenzyme M2 acts as a kinase for STAT3 (Gao, Wang, Yang, Liu, &
Liu, 2012). Reduced glycolytic flux may lead to lower expression of
this enzyme, reducing STAT3 signaling. This would lead to a reduced
inflammatory response. Alternatively, the reduced glycolytic rate may
prevent the production of carbon intermediates required for cytokine
production, through limiting the repurposing of TCA cycle enzymes
(Menk et al., 2018; Williams, O'Neill, & O'Neill, 2018). This would
result in a negative feedback loop reducing the inflammatory response
(Caslin et al., 2018; McGettrick & O'Neill, 2013). It has been reported
that in macrophages 2-DG reduces mitochondrial function indepen-
dently of glycolytic function (Wang et al., 2018); however, in our data
there was no change in oxidative rate as a result of 2-DG treatment.
This suggests that attenuation of the LPS-induced inflammatory
response in the presence of 2-DG was likely a result of glycolytic inhi-
bition rather than modulation of mitochondrial metabolism, but fur-
ther investigation would be required to confirm this.
In conclusion, we have shown that astrocytes have a rapid and
flexible metabolic response to LPS-induced inflammatory insult. This
metabolic response was abolished through inhibition of canonical NF-
κB signaling using the pharmacological inhibitor TPCA-1, implicating
this pathway as a major regulator of inflammatory metabolism in
astrocytes. Furthermore, pharmacological inhibition of NF-κB signal-
ing was sufficient to impact metabolism in astrocytes, independent of
inflammation, suggesting an integral role for NF-κB in basal astrocyte
metabolism. In support of our hypothesis, inhibition of glycolysis
attenuated cytokine release from astrocytes, and resulted in inhibition
of LPS-induced NF-kB phosphorylation, suggesting that glycolysis in
astrocytes is essential for maintaining an inflammatory response.
Together these data indicate that in astrocytes metabolic adaptations
are necessary for the full inflammatory response to LPS and, in turn,
inhibiting NF-κB signaling is sufficient to impact basal metabolism.
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